Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events

Nivolumab is a recently approved medication for the treatment of unresectable malignant melanoma. Many immune-related adverse events (irAEs) associated with nivolumab have been reported, such as pneumonitis, hepatitis, dermatitis, and thyroiditis. Prednisolone can effectively treat irAEs. However, i...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Case Rep Oncol
Hlavní autoři: Imafuku, Keisuke, Yoshino, Koji, Yamaguchi, Kei, Tsuboi, Satoshi, Ohara, Kuniaki, Hata, Hiroo
Médium: Artigo
Jazyk:Inglês
Vydáno: S. Karger AG 2017
Témata:
Case Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5422733/
https://ncbi.nlm.nih.gov/pubmed/28512413
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000463379
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky